Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | KLK7 | P49862 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20503925 | 0.90 | JAK2 (0.55) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL942191 | 0.90 | JAK2 (0.55) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL697850 | 0.90 | JAK2 (0.55) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL22906774 | 0.89 | PRMT5 (0.44) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL25072145 | 0.89 | ABCB1 (0.45) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL2387673 | 0.89 | PRMT5 (0.47) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL25072144 | 0.88 | ABCB1 (0.49) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL25071860 | 0.88 | NR1H2 (0.51) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL25071848 | 0.88 | ABCB1 (0.45) | PRMT5WDR77JAK2JAK1STS | |
| SCHEMBL16903410 | 0.88 | JAK2 (0.44) | PRMT5WDR77JAK2JAK1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452977-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115142-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2651898-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | Agios Pharmaceuticals, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012151448-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083246-A1 | NOVEL N- (4- (AZETIDINE - 1 - CARBONYL) PHENYL) - (HETERO - ) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591342-B2 | Heterocyclic compound, application thereof and pharmaceutical composition comprising same | ENPP2, ATXN10, PCSK9 | PRMT5 4197/4885WDR77 2476/4885JAK2 856/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | PRMT5 2898/4885WDR77 3895/4885JAK2 1688/4885 |
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | PRMT5 735/4885WDR77 2662/4885JAK2 323/4885 |
| US-20140155374-A1 | METHODS OF USING PYRUVATE KINASE ACTIVATORS | PCK1, PDK3, PDK2 | PRMT5 3368/4885WDR77 3401/4885JAK2 2122/4885 |
| US-20140073625-A1 | NOVEL N-(4-(AZETIDINE-1-CARBONYL) PHENYL) - (HETERO-) ARYLSULFONAMIDE DERIVATIVES AS PYRUVATE KINASE M2 (PMK2) MODULATORS | PDK2, PDK3, PDK4 | PRMT5 723/4885WDR77 3428/4885JAK2 612/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | PRMT5 2563/4885WDR77 4334/4885JAK2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.